Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, Finland, Netherlands, Switzerland, Sweden, Taiwan, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Metrics to compare | BAVA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBAVAPeersSector | |
---|---|---|---|---|
P/E Ratio | 14.0x | −4.3x | −0.5x | |
PEG Ratio | 0.45 | −0.08 | 0.00 | |
Price/Book | 1.6x | 1.9x | 2.6x | |
Price / LTM Sales | 3.0x | 5.8x | 3.2x | |
Upside (Analyst Target) | - | 242.1% | 41.6% | |
Fair Value Upside | Unlock | 9.7% | 6.0% | Unlock |